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Paget-Schroetter syndrome (PSS) is a rare form of thoracic outlet syndrome caused by axillosubclavian vein thrombosis which
typically presents in healthy young adults. Prompt therapy, traditionally by means of catheter-directed thrombolysis (CDT) prior
to definitive surgery, can prevent the subsequent onset of postthrombotic syndrome (PTS) and considerable disability. As CDT
is associated with major haemorrhage and high overall treatment cost, pharmacomechanical thrombectomy (PMT) seems to be
an attractive alternative which combines pharmacological thrombolysis with mechanical clot disruption. The Trellis-8 peripheral
infusion catheter is an example of such a treatment which provides topical thrombolysis in an isolated zone. We describe the use of
the Trellis-8 PMT system in the successful management of three patients with PSS.
1. Introduction
Paget-Schroetter syndrome (PSS) is the consequence of
axillosubclavian vein thrombosis arising from thoracic outlet
syndrome. Typically occurring in active young adults, it is
the consequence of repetitive micro trauma to an abnormally
stenotic subclavian vein and results in acute or acute-on-
chronic thrombosis [1].
Serious sequelae can result from untreated PSS, including
pulmonary embolism (PE) [2] and postthrombotic syndrome
(PTS) [3]. Prompt intervention is therefore necessary and
must combine the removal of thrombus with correction of
venous stenosis: usually by means of thrombolysis, percuta-
neous venoplasty, and surgical decompression of the thoracic
outlet [1].
Catheter-directed thrombolysis (CDT) has become the
standard of thrombolytic care in many institutions [1, 4, 5]
but is associated with several disadvantages including major
systemic haemorrhage [4, 6] and high overall treatment cost
[7]. Pharmacomechanical thrombectomy (PMT) addresses
these disadvantages by combiningmechanical clot disruption
and pharmacological thrombolysis within an isolated zone.
Although PMT has been investigated in lower-limb DVT [5],
only a few reports are dedicated to use in upper-limb DVT
[8–10].
PMT devices include the AngioJet system and the Trellis-
8 device (Covidien, Santa Clara, CA) [5, 10, 11]. Whilst the
AngioJet system employs a power-pulse spray technique, the
Trellis-8 is a peripheral infusion catheter designed to isolate
the thrombolytic zone with proximal and distal compliant
balloons, confine themechanical disruptive process, and pre-
vent spread of the thrombolytic agent. Following physical clot
disruption using a wire oscillating at high frequency within
the vein, the resultant product (including the thrombolytic)
is aspirated into a syringe prior to balloon deflation [5].
We describe three cases of PSSmanaged in our institution
with PMT via the Trellis-8 device prior to first rib resection.
2. Case Report
2.1. Case 1. An 18-year-old male presented to the emergency
department with a three-day history of pain, swelling, and
discolouration in the left arm and clinical diagnosis of upper
limb deep vein thrombosis was made.
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Figure 1: (a) Fluoroscopic image showing the distal compliant balloon of the Trellis-8 device inflated in the brachiocephalic vein and the
proximal balloon inflated in the subclavian vein. (b) Aspirated thrombus following PMT.There is a mix of fresh and chronic thrombi.
Catheter venography demonstrated occlusion of the left
subclavian vein around the first rib with extensive thrombus
and collateralised flow, typical of PSS. The brachiocephalic
vein and superior vena cava were patent.
Under local anaesthesia, the brachial vein was punctured
using ultrasound guidance and a 5 French micropuncture
kit (Cook, Bloomington, IN). An 8 French, 9 cm Brite-tip
sheath (Cordis, Miami, FL) was placed in the brachial vein
distal to the thrombus, and the occlusion was crossed with
a hydrophilic 0.035󸀠󸀠 wire (Terumo Corp, Japan). 5000 units
of unfractionated heparin were given via the sheath. An 8
French, 15 cmTrellis-8 device (Covidien,Mansfield,MA)was
placed across the lesion and the balloons inflated. The distal
balloon was positioned in the brachiocephalic vein and the
proximal balloon in the axillary vein (Figure 1(a)), isolating
the thrombus from the systemic circulation. The Trellis
procedure was performed for 10 minutes with concomitant
infusion of 10mg of recombinant tissue plasminogen activa-
tor (rT-PA). The product was aspirated through the device
(Figure 1(b)) and into a 6 French, 55 cm Flexor sheath (Cook,
Bloomington, IN).
Venoplasty was then performed on the tight, irregular
stenosis of the subclavian vein as it crossed the first rib
using an 8 × 40mm fox plus balloon catheter (Abbott,
IL). An intravenous unfractionated heparin infusion was
commenced at 1000 u per hour, and the patient was listed for
emergency first rib resection (within 2 hours). Our procedure
was well tolerated by the patient with no requirements for
sedoanalgesia.
Repeating venography the following day showed a resid-
ual stenosis which responded to 10mm balloon venoplasty.
Subsequent duplex studies at 4 days and 6 weeks showed a
patent vein with no residual stenosis.
At discharge, anticoagulation using warfarin was com-
menced to achieve a target international normalised ratio
(INR) of between 2.5 and 3.5. By six months, the patient was
well with minimal swelling in the arm, anticoagulation was
discontinued, and he has resumed his normal activities.
2.2. Case 2. A26-year-old female presented to the emergency
department with a history of sudden-onset left arm pain and
swelling. Past medical history included recent commence-
ment of the oral contraceptive pill and a first-degree relative
with DVT.
Venography revealed occlusive thrombus in the axil-
lary and subclavian vein with extensive collateralisation
(Figure 2(a)). PMT was performed using the Trellis-8 device
(method as described previously) and 10mg of rT-PA. A
venous stenosis, typical of PSS, was demonstrated at the level
of the first rib (Figure 2(b)), and the patient was transferred
to the operating theatre for first rib resection.
The arm swelling rapidly reduced, and the patient was
discharged on full anticoagulation. She has been lost to
followup.
2.3. Case 3. A 57-year-old male with positive antiphos-
pholipid antibodies developed acute right arm swelling
following strenuous exercise. Venous Doppler ultrasound
demonstrated occlusive thrombus in the right subclavian
and brachial veins. He underwent PMT with the Trellis-
8 device using 10mg rT-PA. Angiographic results were
excellent (Figure 3) and the patient was commenced on
lifelong warfarin for the underlying thrombophilia under
haematological advice.
The patient was discharged following resolution of his
symptoms and remain well at 6-month followup.
3. Discussion
Paget-Schroetter syndrome is a consequence of an anatom-
ically deranged thoracic outlet, most commonly caused by
congenital bands, cervical ribs, scalenus tendon hypertrophy,
or variant insertion of the costoclavicular ligament. Con-
sequently, normal upper-limb movements provide insult to
the subclavian vein which responds with venous intimal
hypertrophy, chronic inflammation, peri-venular fibrosis and
acute or acute-on-chronic thrombosis.
Presenting features include upper-limb pain, heaviness,
swelling and cyanosis and are often preceded by a history
of strenuous exercise or trauma. The influence of inherited
thrombophilic disorders on this condition is unresolved [1].
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Figure 2: (a) Digital subtraction venogram showing occlusive thrombus in the axillary and subclavian veins with extensive collateralisation.
(b) Digital subtraction venogram following PMT. Flow through the axillary and subclavian veins has been restored with minimal residual
thrombus. A stenosis is seen in the first rib.
Figure 3: Digitial subtraction venogram following PMT, showing
complete recanalisation of the occluded subclavian vein.
Postthrombotic syndrome (PTS) is a complication of
venous thrombosis and has recently been recognised in
upper-limb DVT. With an overall incidence of 7%–46% [3],
it comprises a constellation of chronic pain, paraesthesia,
heaviness, and functional limitation which can significantly
impact patients’ quality of life.
Although jugulosubclavian vein bypass and patch veno-
plasty have been described in the management of PTS [12],
supportive measures are mainstay. As such, the aggressive
and early treatment of PSS is paramount. Management of
PSS usually incorporates thrombolytic therapy, percutaneous
venoplasty, and surgical decompression of the thoracic outlet
[1, 8, 9]. The need for and timing of surgery is debated, with
some investigators reserving surgery for those with persistent
or recurrent symptoms following thrombolysis, and others
preferring early decompression for all patients [1].
Catheter-directed thrombolysis has become standard
practice in many institutions prior to surgical management.
However, this often requires Intensive Care Unit (ICU)
admission, regular blood sampling and repeated angiography
to assess treatment response. Median time to complete
resolution in the upper-limb DVT averages 24–48 hours [8,
10], and CDT alone may not provide complete treatment [7]
with major haemorrhage as a well-recognized complication
[4, 6]. To this end, costs of CDT can be considerable.
Pharmacomechanical thrombectomy obviates the need
for ICU admission and eliminates the systemic effects of
thrombolytic agents. In particular, the Trellis-8 system was
shown to have a significantly greater rate of clot lysis (93%)
in comparison with CDT (79%) in a recent meta-analysis
of published trials [7]. Furthermore, the time to lysis was
substantially shorter with Trellis-8 (2 minutes versus 24
hours).
As Trellis-8 requires lower doses of a thrombolytic agent
which is confined to the treatment zone, it is associated with
lower rate of haemorrhagic complications, a shorter time
in the angiography suite, and minimal (if any) time in the
ICU. Consequently, Trellis-8 has been shown to confer an
economic advantage to CDT [7, unpublished data courtesy
of Dr. G. O’Sullivan, Galway, Ireland].
The Trellis-8 catheter has several advantages over other
PMT devices. Firstly, there is no significant systemic throm-
bolysis evidenced by laboratory markers (e.g., fibrinogen)
[11] which decreases the risk of further haemorrhage and
permits other interventionswhichmay be required all around
thrombolysis. This is particularly relevant to patients with
PSS where immediate surgery is often required. Secondly,
by isolating and extracting thrombus, there is probably a
reduced risk of the pulmonary or distal embolic complica-
tions described with the use of other PMT devices [11, 13].
However, certain issues require careful consideration
when using the Trellis-8 infusion catheter. Firstly, although
thrombolytic doses and the risk of haemorrhage are reduced,
the overall safety of Trellis-8 in upper-limb PMThas not been
formally evaluated in clinical trials. Additionally, concerns
have been raised regarding the systemic effects of PMT, for
example, the induction of bradyarrhythmias [14]. Further-
more, the cost advantages of Trellis-8 have only been proven
in lower-limb DVT. Economic advantages of its use in upper-
limbDVTwhere the extent and burden of thrombosismay be
less are yet to be evaluated. Finally, although the introduction
of large calibre sheaths into brachial veins may raise concerns
of technical feasibility and complication rate, this has not
been an issue in our experience.
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4. Conclusion
PSS is a condition of young, healthy, and active patients
with potentially serious long-term sequelae if untreated or
undertreated. We have described three cases of successful
treatment of PSS incorporating the Trellis-8 peripheral infu-
sion catheter. PMT has several advantages over CDT in the
management of PSS as a precursor to surgery, and the Trellis-
8, which specifically provides isolated PMT, seems to be safe,
effective and well tolerated in this patient population. This
paper seeks to assist in raising the awareness of the clinical
and venographic features of PSS and provide additional
management options for the endovascular specialist.
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